Up to 84% of Adult Asthma Patients Present With Type 2 Inflammation1,2
Your appropriate patients with Type 2 inflammation, which can be both systemic and local, may benefit from DUPIXENT today3-5
Explore how DUPIXENT may help control symptoms in different
types of patients
Your appropriate patients with Type 2 inflammation, which can be both systemic and local, may benefit from DUPIXENT today3-5
She is fearful that an asthma
attack will prevent her from
seeing friends and family
EOS 155 cells/µL
IgE 380 IU/mL
Difficulty breathing makes
him nervous that he may
miss out on quality time
with his
young son
EOS 320 cells/µL
IgE 430 IU/mL
FeNO 40 ppb
Biomarker testing not
required for this patient type
The burden of sudden
weight gain has left her
feeling discouraged
Patient profiles are representative and are not actual DUPIXENT patients.
Examples of patients with an eosinophilic phenotype or with OCS-dependent asthma.
FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist.
for 99% of OCS-dependent asthma patients who are commercially insured4